Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Jade Biosciences, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Mark Eisner (Form 8-K filed 2026-06-26). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Bellevue Group Ag (filed 2026-08-14).
Who is behind it
Jade Biosciences, Inc.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Bellevue Group Ag | 5% |
| Schedule 13G/A, 2026-08-14 | Venrock Healthcare Capital Partners Iii, L.P. | 8.3% |
| Schedule 13G, 2026-07-17 | Paradigm Biocapital Advisors LP | 5.1% |
| Schedule 13G/A, 2026-07-08 | Janus Henderson Group LTD. | 10.6% |
| Schedule 13D/A, 2026-06-09 | Fairmount Funds Management LLC | 19.99% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 6.3% |
| Schedule 13G/A, 2026-04-27 | Blackrock, Inc. | 4.7% |
| Schedule 13D/A, 2026-03-05 | Sofinnova Venture Partners X, L.P. ("Svp X") | 0.3% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-26 | Mark Eisner | appointed | ||
| Form 8-K, 2026-04-22 | Andrew King | President | appointed | 2026-04-18 |
Money raised
Latest IPO step: Jade Biosciences, Inc. filed to go public (S-1, 2025-12-22).
IPO filings: S-1, 2025-12-22, S-1, 2025-11-14, RW, 2024-11-25; ticker JBIO on Nasdaq Capital Market.
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/jade-biosciences